4.6 Article

Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine

期刊

MICROORGANISMS
卷 9, 期 6, 页码 -

出版社

MDPI
DOI: 10.3390/microorganisms9061315

关键词

SARS-CoV2; mRNA vaccine; health care workers; whole blood T cell assay; coordinate immunity

资金

  1. Italian Ministry of Health
  2. Esselunga S.p.A. [88/2021]

向作者/读者索取更多资源

The study demonstrates that the BNT162b2 mRNA vaccine can induce both humoral and cell-mediated immune responses against spike peptides in nearly all healthcare workers without previous SARS-CoV-2 infection, with a moderate inverse correlation with age in the anti-RBD response.
Vaccination is the main public health measure to reduce SARS-CoV-2 transmission and hospitalization, and a massive worldwide scientific effort resulted in the rapid development of effective vaccines. This work aimed to define the dynamics of humoral and cell-mediated immune response in a cohort of health care workers (HCWs) who received a two-dose BNT162b2-mRNA vaccination. The serological response was evaluated by quantifying the anti-RBD and neutralizing antibodies. The cell-mediated response was performed by a whole blood test quantifying Th1 cytokines (IFN-gamma, TNF-alpha, IL-2), produced in response to spike peptides. The BNT162b2-mRNA vaccine induced both humoral and cell-mediated immune responses against spike peptides in virtually all HCWs without previous SARS-CoV-2 infection, with a moderate inverse relation with age in the anti-RBD response. Spike-specific T cells produced several Th1 cytokines (IFN-gamma, TNF-alpha, and IL-2), which correlated with the specific-serological response. Overall, our study describes the ability of the BNT162b2 mRNA vaccine to elicit a coordinated neutralizing humoral and spike-specific T cell response in HCWs. Assessing the dynamics of these parameters by an easy immune monitoring protocol can allow for the evaluation of the persistence of the vaccine response in order to define the optimal vaccination strategy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Editorial Material Infectious Diseases

Polio is back? The risk of poliomyelitis recurrence globally, and the legacy of the severe acute respiratory syndrome coronavirus 2 pandemic

Concetta Castilletti, Maria Rosaria Capobianchi

CLINICAL MICROBIOLOGY AND INFECTION (2023)

Article Clinical Neurology

Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies

Alessandra Aiello, Andrea Coppola, Serena Ruggieri, Chiara Farroni, Anna Maria Gerarda Altera, Andrea Salmi, Valentina Vanini, Gilda Cuzzi, Linda Petrone, Silvia Meschi, Daniele Lapa, Aurora Bettini, Shalom Haggiag, Luca Prosperini, Simonetta Galgani, Maria Esmeralda Quartuccio, Nazario Bevilacqua, Anna Rosa Garbuglia, Chiara Agrati, Vincenzo Puro, Carla Tortorella, Claudio Gasperini, Emanuele Nicastri, Delia Goletti

Summary: COVID-19 vaccine booster strengthens humoral and Th1-cell responses and increases T-EM cells in patients with multiple sclerosis.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)

Article Infectious Diseases

Benefits and Safety of Empiric Antibiotic Treatment Active Against KPC-K. pneumoniae in Febrile Neutropenic Patients with Acute Leukemia Who are Colonized with KPC-K. pneumoniae. A 7-Years Retrospective Observational Cohort Study

Alessandra Micozzi, Clara Minotti, Saveria Capria, Claudio Cartoni, Silvia Maria Trisolini, Giovanni Manfredi Assanto, Walter Barberi, Maria Luisa Moleti, Stefania Santilli, Maurizio Martelli, Giuseppe Gentile

Summary: The purpose of this study was to evaluate the benefits and safety of empiric antibiotic treatment (EAT) active against KPC-K. pneumoniae in febrile neutropenic patients with acute leukemia (AL) who are colonized by KPC-K. pneumoniae. The results showed that EAT with CAZAVI-based combinations had better outcomes compared to colistin-based EAT. CAZAVI-containing EAT was the independent factor for an overall successful response.

INFECTION AND DRUG RESISTANCE (2023)

Letter Infectious Diseases

People with asymptomatic or unrecognised infection potentially contribute to monkeypox virus transmission

Silvia Accordini, Maddalena Cordioli, Elena Pomari, Evelina Tacconelli, Concetta Castilletti

LANCET MICROBE (2023)

Article Virology

Profiling the acute phase antibody response against mpox virus in patients infected during the 2022 outbreak

Francesca Colavita, Giulia Matusali, Valentina Mazzotta, Aurora Bettini, Daniele Lapa, Silvia Meschi, Massimo Francalancia, Carmela Pinnetti, Licia Bordi, Klizia Mizzoni, Sabrina Coen, Enrico Girardi, Francesco Vaia, Emanuele Nicastri, Andrea Antinori, Fabrizio Maggi

Summary: This study describes the short-term kinetics of the antibody response in MPXV-infected patients during the 2022 multicountry outbreak. The results show that IgG, IgM, and IgA antibodies were detected as early as 4 days after symptom onset, while neutralizing antibodies were detectable after 1 week. There were no significant differences in antibody levels regardless of smallpox vaccination status, HIV positivity, or disease severity. Lower levels of IgM and IgG were observed in patients treated with antivirals.

JOURNAL OF MEDICAL VIROLOGY (2023)

Article Medicine, General & Internal

Subjects who developed SARS-CoV-2 specific IgM after vaccination show a longer humoral immunity and a lower frequency of infection

Chiara Piubelli, Alessandra Ruggiero, Lucia Calciano, Cristina Mazzi, Concetta Castilletti, Natalia Tiberti, Sara Caldrer, Matteo Verze, Silvia Stefania Longoni, Simone Accordini, Zeno Bisof, Donato Zipeto

Summary: The development of SARS-CoV-2-specific IgM after vaccination is associated with higher levels of SARS-CoV-2 neutralizing IgG. This study aims to assess whether IgM development is also associated with longer-lasting immunity. The results show that IgM development after vaccination is associated with higher levels of IgG antibodies in the short and long term, and most individuals who developed IgM antibodies did not experience infection, suggesting a lower risk of infection.

EBIOMEDICINE (2023)

Article Medicine, General & Internal

Detection of SARS-CoV-2 Variants via Different Diagnostics Assays Based on Single-Nucleotide Polymorphism Analysis

Eliana Specchiarello, Giulia Matusali, Fabrizio Carletti, Cesare Ernesto Maria Gruber, Lavinia Fabeni, Claudia Minosse, Emanuela Giombini, Martina Rueca, Fabrizio Maggi, Alessandra Amendola, Anna Rosa Garbuglia

Summary: In this study, the performance of three methods for detecting SARS-CoV-2 variants was evaluated. Novaplex showed the highest ability to detect the Omicron subtype, while Allplex showed the highest ability to detect the Delta subtype. At the same time, Novaplex was able to resolve samples that could not be determined by TaqPath. The results of this study demonstrate the high efficiency of SNP-based methods for identifying viral variants.

DIAGNOSTICS (2023)

Article Medicine, General & Internal

Evaluation of a ddPCR Commercial Assay for the Absolute Quantification of the Monkeypox Virus West Africa in Clinical Samples

Elena Pomari, Antonio Mori, Silvia Accordini, Annalisa Donini, Maddalena Cordioli, Evelina Tacconelli, Concetta Castilletti

Summary: A commercial ddPCR assay was evaluated for the detection of the West African clade of monkeypox virus (MPXV) in clinical samples. The assay showed good performance for skin lesions and rectal swabs.

DIAGNOSTICS (2023)

Article Biochemistry & Molecular Biology

SARS-CoV-2 Breakthrough Infections According to the Immune Response Elicited after mRNA Third Dose Vaccination in COVID-19-Naive Hospital Personnel

Annapaola Santoro, Andrea Capri, Daniele Petrone, Francesca Colavita, Silvia Meschi, Giulia Matusali, Klizia Mizzoni, Stefania Notari, Chiara Agrati, Delia Goletti, Patrizio Pezzotti, Vincenzo Puro

Summary: This study investigated the incidence of vaccine breakthrough infections in COVID-19-free individuals after receiving the mRNA third dose vaccine, based on B- and T-cell immune responses. The results showed that there were no protective thresholds for SARS-CoV-2 infection in terms of antibody levels or cellular immune response. Therefore, measuring vaccine-induced humoral immune response is not recommended as a marker for assessing protective immunity against SARS-CoV-2.

BIOMEDICINES (2023)

Letter Immunology

Asymptomatic Monkeypox virus Infection in Subjects Presenting for MVA-BN Vaccine

Giulia Matusali, Valentina Mazzotta, Pierluca Piselli, Aurora Bettini, Francesca Colavita, Sabrina Coen, Francesco Vaia, Enrico Girardi, Andrea Antinori, Fabrizio Maggi

CLINICAL INFECTIOUS DISEASES (2023)

Article Immunology

Older Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine

Andrea Picchianti-Diamanti, Assunta Navarra, Alessandra Aiello, Bruno Lagana, Gilda Cuzzi, Andrea Salmi, Valentina Vanini, Fabrizio Maggi, Silvia Meschi, Giulia Matusali, Stefania Notari, Chiara Agrati, Simonetta Salemi, Roberta Di Rosa, Damiano Passarini, Valeria Di Gioia, Giorgio Sesti, Fabrizio Conti, Francesca Romana Spinelli, Angela Corpolongo, Maria Sole Chimenti, Mario Ferraioli, Gian Domenico Sebastiani, Maurizio Benucci, Francesca Li Gobbi, Anna Paola Santoro, Andrea Capri, Vincenzo Puro, Emanuele Nicastri, Delia Goletti

Summary: Breakthrough infections (BIs) in rheumatoid arthritis (RA) patients after a COVID-19 vaccination booster dose were analyzed. Older age, receiving conventional synthetic disease modifying antirheumatic drugs (csDMARDs), and higher neutralising antibody titres were identified as protective factors, while anti-IL6R treatment and anti-CD20 therapy increased the risk. The incidence of hospitalization for BIs was significantly higher in RA patients compared to healthcare workers.

VACCINES (2023)

Article Immunology

Torquetenovirus Loads in Peripheral Blood Predict Both the Humoral and Cell-Mediated Responses to SARS-CoV-2 Elicited by the mRNA Vaccine in Liver Transplant Recipients

Claudia Minosse, Giulia Matusali, Silvia Meschi, Germana Grassi, Massimo Francalancia, Gianpiero D'Offizi, Pietro Giorgio Spezia, Anna Rosa Garbuglia, Marzia Montalbano, Daniele Focosi, Enrico Girardi, Francesco Vaia, Giuseppe Maria Ettorre, Fabrizio Maggi

Summary: TTV viremia levels before vaccination in liver transplant recipients can predict their serum antibody response and cell-mediated immunity, but are not associated with serum neutralizing antibody titers.

VACCINES (2023)

Article Immunology

Evaluation of Cross-Immunity to the Mpox Virus Due to Historic Smallpox Vaccination

Giulia Matusali, Elisa Petruccioli, Eleonora Cimini, Francesca Colavita, Aurora Bettini, Eleonora Tartaglia, Settimia Sbarra, Silvia Meschi, Daniele Lapa, Massimo Francalancia, Licia Bordi, Valentina Mazzotta, Sabrina Coen, Klizia Mizzoni, Alessia Beccacece, Emanuele Nicastri, Luca Pierelli, Andrea Antinori, Enrico Girardi, Francesco Vaia, Alessandro Sette, Alba Grifoni, Delia Goletti, Vincenzo Puro, Fabrizio Maggi

Summary: This study found that a high proportion of individuals who received the smallpox vaccine 40 to 60 years ago have humoral cross-immunity to MPXV, while a smaller group of vaccinated individuals showed a T-cell-specific response against MPXV.

VACCINES (2023)

暂无数据